title: Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells.
abstract: The transduction efficiencies of immunoselected rhesus macaque (Macaca mulatta) CD34+ cells and colony-forming progenitor cells based on polymerase chain reaction (PCR) analysis were comparable for an amphotropic Moloney murine leukemia virus (MLV) retroviral vector and a retroviral vector derived from the gibbon ape leukemia virus (GaLV) packaging cell line, PG13. On performing autologous transplantation studies using immunoselected CD34+ cells transduced with the GaLV envelope (env) retroviral vector, less than 1% of peripheral blood (PB) contained provirus. This was true whether bone marrow (BM) or cytokine-mobilized PB immunoselected CD34+ cells were reinfused. This level of marking was evident in two animals whose platelet counts never fell below 50,000/microliter and whose leukocyte counts had recovered by days 8 and 10 after having received 1.7 x 10(7) or greater of cytokine-mobilized CD34+ PB cells/kg. Reverse transcriptase(RT)-PCR analysis of CD34+ subsets for both the GaLV and amphotropic receptor were performed. The expression of the GaLV receptor was determined to be restricted to CD34+ Thy-1+ cells, and both CD34+ CD38+ and CD34+ CD38dim cells, while the amphotropic receptor was present on all CD34+ cell subsets examined. Our findings suggest that, in rhesus macaques, PG13-derived retroviral vectors may only be able to transduce a subset of CD34+ cells as only CD34+ Thy-1+ cells express the GaLV receptor.
authors.affiliation: Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Bunnell
authors.forename: K A
authors.initials: KA
authors.lastname: Kluge
authors.forename: S Q
authors.initials: SQ
authors.lastname: Lee-Lin
authors.forename: E R
authors.initials: ER
authors.lastname: Byrne
authors.forename: D
authors.initials: D
authors.lastname: Orlic
authors.forename: M E
authors.initials: ME
authors.lastname: Metzger
authors.forename: B A
authors.initials: BA
authors.lastname: Agricola
authors.forename: R P
authors.initials: RP
authors.lastname: Wersto
authors.forename: D M
authors.initials: DM
authors.lastname: Bodine
authors.forename: R A
authors.initials: RA
authors.lastname: Morgan
authors.forename: R E
authors.initials: RE
authors.lastname: Donahue
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000818:Animals; D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000276:immunology; D017989:Leukemia Virus, Gibbon Ape / Q000235:genetics*; D008253:Macaca mulatta; D008979:Moloney murine leukemia virus / Q000235:genetics*; D009244:NAD+ Nucleosidase; D018800:Thy-1 Antigens; D014162:Transfection / Q000379:methods*
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D018800:Thy-1 Antigens; D036541:ADP-ribosyl Cyclase; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1